Syntex' mycophenolate mofetil (MMF)
Executive Summary
NDA for the oral immunosuppressant is filed Nov. 9 for prevention of acute kidney transplantation rejection and to treat refractory acute kidney graft rejection, Syntex announces Nov. 22. Syntex parent Roche has submitted registration applications for the drug in 12 European and Scandinavian countries, where it plans to market MMF. The NDA contains data in four clinical trials in approximately 1,650 patients